Quanterix Q3 revenue rises 6.3% sequentially

Overview

• US biomarker diagnostics firm's Q3 revenue rose 6.3% sequentially, but fell yr/yr

• Net loss narrowed 36% from prior year to $21.6 mln in Q3

• Company cites new partnerships, expanded Alzheimer’s test coverage, and China approvals as growth drivers

Outlook

• Quanterix narrows 2026 revenue outlook to $142-146 mln

• Company expects 2026 adjusted gross margin of 48-50%

• Quanterix expects to end 2026 with about $70 mln in cash and no debt

Result Drivers

• COMMERCIAL REORGANIZATION - Co said sequential revenue growth reflected improvement across all businesses after reorganizing teams and adding new leadership

• NEW PARTNERSHIPS - Co added two new commercial partnerships with regional clinical labs, generating new diagnostics revenue opportunities

• REGULATORY APPROVALS IN CHINA - Co said new regulatory approvals advanced access to neurology biomarker testing in China via partnerships with Innovita Biological Technology

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for Quanterix Corporation is $3.00, about 3.6% above its November 6 closing price of $2.90

Reuters Recommended Reads

• Nov 9 - Editas Medicine Q3 net loss narrows

• Nov 9 - Immunovant Q2 net loss narrows on lower R&D costs

• Nov 6 - UK's Immunocore Q3 loss misses estimates on higher R&D spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)